AstraZeneca

News

AZ extends cardiovascular pipeline with $2bn CSPC deal

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut

News

AZ, Avillion's Airsupra aces asthma rescue therapy trial

A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug outperformed a standard therapy.

News

AZ gets sought-after lung cancer approval for Tagrisso

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targete

News

Respiratory biotech Upstream joins Nasdaq IPO surge

Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.

News

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

News

ESMO: Enhertu shows its worth in brain metastases

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

AZ extends cardiovascular pipeline with $2bn CSPC deal

AZ, Avillion's Airsupra aces asthma rescue therapy trial

AZ gets sought-after lung cancer approval for Tagrisso

Respiratory biotech Upstream joins Nasdaq IPO surge

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

ESMO: Enhertu shows its worth in brain metastases

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks